SecBot SecBot
424B5 ·Filed Apr 13, 2026

RVMDW

Revolution Medicines, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed7mo ago SEC0001193125-26-152972
Notable filing: 424B5
Actionable Insight ▼ Bearish

The dual capital raising through debt and equity significantly increases financial risk. The convertible notes are unsecured and structurally subordinated, making them riskier than secured debt. The concurrent stock offering will dilute existing shareholders. Investors should be concerned about the company's ability to service this increased debt load, especially given its clinical-stage status and lack of revenue.

DirectionBearish
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines is raising $250 million through a convertible senior notes offering, with a concurrent $750 million common stock offering. The notes are unsecured and rank below existing secured debt, increasing financial risk.

Key Facts

  • Company is offering $250 million in convertible senior notes due 2033
  • Concurrent common stock offering of $750 million
  • Notes are senior unsecured obligations, structurally subordinated to subsidiary liabilities
  • Company had $268.4 million in royalty sale liabilities as of December 31, 2025
  • No cash dividends paid on common stock, no plans to pay in foreseeable future

Financial Impact

$250 million in new debt, increasing leverage

debtdilutionleverage

Risk Factors

  • Increased leverage could limit financial flexibility
  • Equity issuance will dilute existing shareholders
  • Unsecured debt ranks below secured obligations in bankruptcy

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-152972
Document: 0001193125-26-152972-index-headers.html0001193125-26-152972
Document: 0001193125-26-152972-index.html0001193125-26-152972
Document: 0001193125-26-152972.txt0001193125-26-152972

Track record

8 reports on RVMDW

Performance horizon

0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: 0.00% at T+1 after the Apr 15, 2026 report. 0 of 3 went positive at some point.

Filters
  1. Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
  2. Apr 16, 202630w ago 8-K Neutral 6/10 Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
  3. Apr 15, 202630w ago 424B5 Neutral 6/10 Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
  4. Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  5. Apr 15, 202630w ago 144 Bearish 6/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  6. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  7. Apr 13, 202631w ago 424B5 Bearish 7/10 Viewing Entry $1.88 No price data
  8. Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
Showing 8 of 8

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026